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Abstract 
Objectives 
To evaluate risks of depression and all-cause mortality, healthcare utilisation costs, and 
treatment adherence in congenital adrenal hyperplasia (CAH) in the UK. 
Design and Methods 
A retrospective, matched-cohort study using UK primary-care data from the Clinical Practice 
Research Datalink linked to hospital and death-certification data. Patients diagnosed with 
CAH and having ≥1 corticosteroid prescription were matched 1:10 to reference subjects. 
Risk of death and lifetime prevalence of depression were compared using Cox regression 
models. Direct financial costs were estimated for healthcare contacts. Treatment adherence 
was measured by medical possession ratio (MPR). 
Results 
605 patients with CAH were identified; 562 were matched. 270 CAH patients (2,700 
controls) were linkable to death-certificate data, with adjusted hazard ratio for all-cause 
mortality 5.17 (95%CI 2.81 to 9.50). Mean (SD) age at death in CAH patients was 54.8 (23.9) 
versus 72.8 (18.0) years in control patients. The prevalence ratio of depression in CAH 
versus control patients was 1.28 (95%CI 1.13 to 1.45). Mean (SD) annual healthcare costs 
were higher in CAH than controls: at age 0–6 years, £7,038 (£14,846) versus £2,879 
(£13,972, p<0.001); 7–17 years, £3,766 (£7,494) versus £1,232 (£2,451, p<0.001); 18–40 
years, £1,539 (£872) versus £1,344 (£1,620, p=0.007); and ≥41 years, £4,204 (£4,863) versus 
£1,651 (£2,303, p<0.001). Treatment adherence was lowest in adults, with 141 (36%) of 396 
eligible patients having an MPR <80%. 
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Conclusions 
This first analysis of CAH in routine UK healthcare suggests that patients with CAH have 
increased mortality, depression, and healthcare utilisation, and low treatment adherence. 
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Introduction 
Congenital adrenal hyperplasia (CAH) comprises a group of genetic disorders in which 
cortisol synthesis is disrupted (1), leading to deficiencies of cortisol and, potentially, 
aldosterone with consequent increased production of androgens. Clinical manifestations of 
classical CAH include acute, life-threatening adrenal crises and androgen excess, resulting in 
genital ambiguity and hirsutism in females, precocious puberty, infertility, and compromised 
quality of life in both men and women(2, 3). A milder, non-classical (not salt-wasting) form 
of the disease can produce symptoms, such as irregular menstrual periods and fertility 
problems later in life, but many patients with non-classical CAH are asymptomatic and most 
are not treated with corticosteroids; the focus of this paper is, therefore, classical CAH. 
The British Paediatric Surveillance Unit has reported that CAH affects approximately 
1:18,000 live-born infants in Great Britain (4). Treatment of CAH since the 1950s has taken 
the form of lifelong replacement therapy with glucocorticoids and, where needed 
mineralocorticoids, although no licensed paediatric dose formulation exists for neonates 
and infants, and there are concerns that the physiological circadian rhythm of cortisol is not 
successfully mimicked by existing products (5, 6). Data from long-term registries have 
suggested that CAH is associated with excess mortality and morbidity risk (3), and this may 
relate to glucocorticoid replacement (2, 7). 
In this retrospective matched-cohort study, we evaluated the burden of CAH in a UK 
population by analysing the risk of depression and all-cause mortality, and estimating 
healthcare use, costs and adherence to oral corticosteroid therapy. 
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Patients and methods 
Data were from: the Clinical Practice Research Datalink (CPRD) primary-care data set and 
linked additional data sets (where eligible): death-certificate data from the Office for 
National Statistics (ONS) and inpatient and outpatient data from the Hospital Episode 
Statistics (HES) for England (8–10). Approval for this study was granted by the CPRD 
Independent Scientific Advisory Committee (reference number 15_203). 
CPRD is an ongoing database of pseudonymized data collected in a non-interventional way 
from participating primary-care practices throughout the UK. At January 2015, it contained 
more than 13 million research-quality patients registered at 684 practices. For more than 7 
million patients (54%) registered with participating English practices, their records can be 
linked with other data sources, notably HES (containing details of every hospital admission 
and outpatient appointment in England) and ONS mortality data (the legal repository for the 
notification of deaths in England and Wales). 
The study population were patients with a CAH diagnosis recorded by Read Code (CPRD) or 
ICD-10 code (HES), as listed in Supplementary Table 1, and drawn from patients flagged by 
CPRD as having acceptable research quality. To substantiate patients’ CAH status we 
required patients to have at least one prescription for a corticosteroid. Where a patient’s 
records included a conflicting diagnosis the record was assessed by an endocrinologist 
(author RJMR) to confirm the CAH diagnosis. The date of the patient’s first CAH record was 
the earlier of their first CAH diagnostic record or their first corticosteroid prescription. The 
patient’s index date, equating to start of follow-up, was the latest of the patient’s first CAH 
record, their registration date, or their general practice’s up-to-standard date (a CPRD 
Page 5 of 37
research-quality indicator). End of follow-up was the earliest of the patient’s death date, 
transfer from the practice, or the practice’s last data-collection date. The entire CAH study 
population participated in the comparative analysis of depression (if matched) and analysis 
of therapy adherence. In the comparative analyses of all-cause mortality and healthcare 
use, we considered patients eligible to participate in the appropriate linkage scheme and 
having index dates within the coverage periods of the linked datasets. In analyses by age 
group, patients were included if they became eligible for inclusion in that age group at any 
time in their follow-up period; patients were then observed while their age-group interval 
was concurrent with the data follow-up period. For comparative analyses, patients with CAH 
were matched with reference (control) patients randomly selected from CPRD patients 
having no record of CAH, adrenal crisis, or other adrenal insufficiency at any time in their 
primary-care and linked HES records. CAH patients were matched 1:10 with control patients 
on year of birth, gender, general practice, registration at case index date, and eligibility for 
linkage to the HES and death-certificate  data sets. The last of these criteria, linkage 
eligibility, was necessary in order to create comparable matched cohorts for analyses based 
on the linked data sets. Control patients inherited the index date of their matched CAH 
patient. 
Study endpoints 
Death and depression: Death was determined from death certification and depression by 
Read Code in CPRD, by ICD-10 code in HES inpatient data, or by the prescription of 
antidepressants. A sensitivity analysis considered only those depression outcomes identified 
by both diagnostic (Read or ICD-10) code and at least one antidepressant prescription.  
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Lifetime prevalence of depression rather than incident occurrence was compared because 
the clustering of apparently incident diagnoses around registration date might have led to 
ascertainment bias in the CAH study arm. Depression was identified not only from ongoing 
records but also from patients’ clinical histories dating from before the start of data follow-
up (from records transferred or transcribed from other general practices or from records 
entered before the practice’s up-to-standard date or in the course of the patient’s previous 
period of registration at the practice). 
Treatment adherence: Medical possession ratio (MPR) was used as a proxy for CAH 
patients’ adherence to oral corticosteroid medications as prescribed. This standard measure 
was calculated as the total days’ supply prescribed over an observation period divided by 
the duration of that observation period (11). An MPR <80% is considered to indicate poor 
compliance (12). 
Healthcare resource use and costs: Primary-care contacts were identified from CPRD’s 
consultation table, and inpatient admissions and outpatient attendances from the linked 
HES inpatient and outpatient data sets, respectively. Resource use and costs were analysed 
in two different subsets of the data: primary-care costs in all CAH and control patients 
regardless of linkage eligibility, followed from start (index date) to end of CPRD data follow-
up; and combined primary- and secondary-care costs in linkage-eligible CAH patients and 
their controls, followed from the later of their index date and the start of HES follow-up to 
the end of combined CPRD and HES follow-up. Given that a proportion of identified patients 
could not be observed in the period in which CAH first presented, sensitivity analyses were 
carried out, selecting only those CAH patients (and their controls) who had data follow-up 
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that included their first record of CAH or closely followed it (within 365 days of first CAH and  
of patient’s year of birth). 
Each primary-care consultation was classified by consultation type (e.g. clinic, surgery, home 
visit) and staff role (e.g. doctor, practice nurse) and then assigned an average cost as listed 
in the Unit Costs of Health and Social Care 2013/2014 from the Personal Social Services 
Research Unit (PSSRU) (13). Where only the average cost per hour was published, the rkload 
Survey (14) was consulted in order to determine the average length of the consultation, 
from which the average cost for that consultation could be calculated. Each inpatient 
admission was allocated a Healthcare Resource Group (HRG) using local payment grouper 
software (15), thereby aggregating spells of patient care into categories that are 
homogenous in terms of resource use. The allocated HRG was then linked to the 2013/2014 
National Tariff (16) and the relevant cost applied depending upon the nature of the spell. 
Additional costs relating to excess length of stay, as defined by the National Tariff, were also 
allocated. Where no cost could be allocated, mean costs were assigned by spell type: 
elective, emergency or day. Where possible, the main specialty recorded for each 
outpatient appointment was used to assign a cost from the 2013/2014 National Tariff (16). 
If a cost could not be applied by main specialty, treatment specialty was used instead. 
Different costs were applied to first and follow-up appointments. Where a specialty was not 
listed in the tariff, costs were applied from the 2013/14 NHS Reference Costs (17). The same 
costs were applied to appointments that were not attended. 
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Statistical methods 
Baseline characteristics of CAH patients and their controls at index date (start of data 
follow-up) were aggregated and compared using the independent t-test or Mann-Whitney U 
test depending upon their distribution. Categorical variables were compared using the chi-
square test. For the survival analysis, Kaplan–Meier curves stratified by study arm were 
produced. Time from index date to death was evaluated using Cox proportional hazards 
modelling, with adjustments for age, sex, Charlson comorbidity index (18), and index year 
(omitting sex where results were presented by gender). The proportional hazards 
assumption was tested by examining the Pearson correlation between Schoenfeld residuals 
and the rank of survival time for cases that had progressed to death. Lifetime prevalence of 
depression was compared between study arms by chi-square test. Rates and costs of health-
service use per person year were calculated and compared between CAH patients and their 
matched controls using the Mann–Whitney U-test. MPR in patients with CAH were 
presented as summary statistics in tabular form. The point prevalence of corticosteroid-
treated CAH patients in the CPRD population was calculated for 30 June 2013 as the number 
of CAH patients with an index date ≤ 30 June 2013 and an end of follow-up ≥ 30 June 2013, 
divided by the CPRD population with a registered status on that date, and presented with 
95% Wilson score confidence intervals.  
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Results 
We identified 1,188 research-quality patients having at least one diagnostic code for CAH in 
the CPRD or linked HES inpatient data. Of these, 67 were excluded because their first CAH 
diagnostic record was dated after the end of CPRD follow-up; a further 41 were excluded 
because they shared a linked identity in HES with another patient; and three with conflicting 
adrenal diagnoses were excluded as probably not having CAH after scrutiny of their CPRD 
and HES histories, leaving 1,077 patients. Of these, 605 (56%) had a record of at least one 
corticosteroid prescription and formed the CAH study population. 354 CAH patients (59%) 
were identified through CPRD data alone, 52 (9%) through HES alone, and 199 (33%) 
through their records in both CPRD and HES. 367 CAH patients (61%) were eligible for 
linkage to the HES and ONS data sets. For the comparative analyses, 562 (93%) CAH patients 
could each be matched with 10 non-exposed, control patients. Patient subsets are 
presented in Supplementary Figure 1. 
Prevalence: 268 CAH patients were prevalent at 30 June 2013, representing a point 
prevalence of 5.84 per 100,000 registered patients (95% Wilson score CI 5.18 to 6.58 per 
100,0000), or one in 17,135 patients (95% CI one in 19,312 to 15,202 patients). 
Baseline characteristics: Table 1 summarises the baseline characteristics of children (<18 
years) and adults (18 years and over) at index date (start of data follow-up). Female children 
with CAH had a mean age of 5.8 years (SD 5.2; median 5, IQR 1 to 9 years) at start of follow-
up; male children had a mean age of 4.5 years (SD 4.8; median 3, IQR 0 to 7 years). The 
mean time from first record of CAH (first diagnostic record or corticosteroid prescription) to 
index date was 2.5 years in girls (SD 4.4; median 0, IQR 0 to 3.1 years) and 1.6 years (SD 3.2; 
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median 0, IQR 0 to 10 years) in boys. For adult women with CAH, the mean age at the start 
of follow-up was 34.3 years (SD 13.7; median 31, IQR 24 to 39 years) and men 37.5 years (SD 
17.4; median 31, IQR 25 to 47 years). The mean time from first CAH to index date was 12.6 
years in women (SD 13.5; median 5.8, IQR 0 to 24.2 years) and 17.2 years (SD 15.0; median 
19.5, IQR 0 to 28.1 years) in men. Adult CAH patients had a higher mean body mass index 
(BMI) than controls: 28.2 (SD 6.5) kg/m2 versus 26.1 (6.1) kg/m2 (median 26.7 [IQR 23.3 to 
31.2] kg/m2 vs 24.8 [22.1 to 29.0] kg/m2; p<0.001), respectively. The smoking profiles of CAH 
and control patients were similar, but a higher proportion of CAH patients described 
themselves as ‘ex-drinkers’ compared with control patients: 4% versus 1% overall (p=0.001), 
3% versus 1% in female patients (p=0.010), and 6% versus 1% in male patients (p=0.037), 
respectively. Thirty-nine (7%) of CAH patients had records of adrenal crisis, 17 (44%) were 
male, 22 (56%) female. Nine CAH patients had ≥1 adrenal crisis while aged 6 years or 
younger, 11 aged 7 to 17 years, 10 aged 18 to 25 years, and 12 aged 26 years or older. There 
were no records of adrenal crisis in the control patients. 
All-cause mortality: 270 CAH patients, matched with 2,700 control patients, were eligible 
for inclusion in the comparison of mortality risk. Mean (SD) age at start of mortality follow-
up was 23.3 (19.7) years in each cohort, with a mean (SD) follow-up of 5.3 (4.3) years in CAH 
patients and 5.8 (4.5) years in control patients. There were 17 deaths amongst the 270 
eligible CAH patients, corresponding to a crude mortality rate of 11.9 deaths per 1,000 
person-years (Table 2). Amongst the 2,700 eligible control patients, there were 41 deaths, 
corresponding to 2.6 deaths per 1,000 person-years. Kaplan–Meier curves for female, male, 
and all patients and stratified by study arm are shown in Figure 1. The adjusted hazard ratio 
(aHR) for all-cause mortality in eligible CAH patients versus their matched controls was 5.95 
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(95% CI 3.35 to 10.56), adjusting for age and sex. When the model was further adjusted to 
include index (start of follow-up) year and baseline Charlson comorbidity index, the aHR was 
5.17 (2.81 to 9.50). In female patients, the aHR was 6.00 (95%CI 2.80 to 12.86), adjusting for 
age, decreasing to 4.69 (2.05 to 10.71) when index year and Charlson index were added to 
the model. In male patients, the aHR was 5.87 (2.41 to 14.26), adjusting for age, increasing 
to 6.81 (2.68 to 17.29) on the inclusion of index year and Charlson index. Mean age at death 
in eligible CAH patients was 54.8 years (SD 23.9; median 62.0, IQR 34.0 to 75.0 years), 
compared with 72.8 years (SD 18.0; median 78.0, IQR 71.0 to 83.0 years) in control patients. 
In female CAH patients, mean age at death was 55.8 years (SD 20.9; median 60.5, IQR 40.0 
to 73.0 years), compared with a mean age of 69.2 years (SD 22.3; median 76.0, IQR 70.25 to 
83.25 years) in female control patients. In male CAH patients, mean age at death was 53.3 
years (SD 27.5; median 72.0, IQR 26.0 to 77.0 years), compared with a mean age of 76.3 
years (SD 11.5; median 80.0, IQR 74.0 to 83.0 years) in male control patients. 
Depression: The lifetime prevalence of depression was 33.5% in CAH patients versus 26.1% 
in control patients, a prevalence ratio of 1.28 (95% CI 1.13 to 1.45, Table 3). In a sensitivity 
analysis in which depression was identified by the presence of both a diagnostic code and an 
antidepressant prescription, the lifetime prevalence decreased in both study arms: 18.3% 
versus 13.2% in CAH patients and control patients, respectively, but the prevalence ratio 
compared with controls remained significantly high: 1.39 (1.15 to 1.68, Supplementary 
Table 2). When analysed by age group (children: ≤17 years, younger adults: 18 to 40 years, 
and older adults: ≥41 years), lifetime prevalence of depression remained higher in CAH 
patients than in control patients, significantly so in children and in the older adults, with 
prevalence ratios 1.47 (95%CI 1.03 to 2.09) and 1.50 (1.30 to 1.74), respectively (Table 3). 
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Lifetime prevalence was higher in female patients than in males in both cohorts and across 
all age groups, but the prevalence ratio compared with controls was higher for male 
patients than for female patients in children and older adults: 2.18 (1.20 to 3.96) in male 
children and 1.22 (0.78 to 1.89) in female children; 1.69 (1.32 to 2.17) in older adult males 
and 1.40 (1.17 to 1.67) in older adult females. The prevalence of depression in male young 
adult CAH patients was similar to controls. In the sensitivity analysis, results by gender and 
age group were similar, with lifetime prevalence reduced but prevalence ratios increased, 
although reduced patient numbers meant that results were statistically significant only in 
older adults (Supplementary Table 2). 
Healthcare costs: Total costs are presented by age group in Table 4, with stratified primary 
and secondary healthcare costs presented in Supplementary Tables 3A–D and healthcare 
resource use in Supplementary Tables 4A–D. Mean (SD) annual total healthcare costs were 
higher for patients with CAH than for controls across all age groups: £7,038 (£14,846) versus 
£2,879 (£13,972) in those aged 0 to 6 years (a ratio of 2.4; p<0.001); £3,766 (£7,494) versus 
£1,232 (£2,451) in those aged 7 to 17 years (3.1; p<0.001); £1,539 (£872) versus £1,344 
(£1,620) in those aged 18 to 40 (1.1; p=0.007); and £4,204 (£4,863) versus £1,651 (£2,303) 
in those aged 41 and older (2.5; p<0.001), respectively (Table 4). Mean total annual costs 
were highest in CAH patients aged 0 to 6 years due to frequent inpatient admissions, 
especially in female patients (Table 4 and Supplementary Tables 3A and 4A) and lowest in 
young adults aged 18 to 40 (Table 4 and Supplementary Tables 3C and 4C). Supplementary 
Tables 5 and 6 detail primary and secondary healthcare resource use and costs, respectively, 
for CAH and control patients irrespective of age. Both resource use and mean annual total 
primary and secondary healthcare costs were significantly higher for patients with CAH 
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versus control patients. Resource use and costs remained significantly higher in the 
sensitivity analysis in which CAH patients were observable from, or shortly after, their first 
CAH record (Supplementary Tables 7 and 8) and when a larger subset of the study 
population was analysed, comprising CAH and control patients regardless of linkage 
eligibility (Supplementary Tables 9 and 10). 
Treatment adherence: Mean (SD) medical possession ratio (MPR) was lowest in adult 
patients: 78.3% (29.8%) in men and 78.5% (29.3%) in women (Table 5). In this age group, 54 
(36%) of the 150 men and 87 (35%) of the 246 women had an MPR that had fallen below 
80% (a marker of non-compliance). Adherence was highest in male patients observed from 
age 0 to 6: mean (SD) MPR 89.7% (22.2%), with 14 patients (15%) non-compliant, and in 
male patients from age 7 to 17: MPR 88.7% (23.3%), with 15 patients (16%) non-compliant. 
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Discussion 
This retrospective, observational study showed that CAH patients had a higher risk of 
mortality and depression, increased healthcare utilisation with accompanying increased 
costs, and poor medication adherence.  
In our study, the adjusted risk of death was more than five times higher in patients with CAH 
than in a reference group of patients having no history of adrenal insufficiency, with the risk 
being higher in males than in females. A similar trend was observed in a Swedish setting (3), 
although the excess risk in patients with CAH (a hazard ratio of 2.3) was lower than that 
observed here and the difference in risk between genders was reversed. Multiple factors 
may have affected the results in the two countries, such as Sweden’s nationwide neonatal 
screening programme for CAH, introduced in 1986, and differences in sample sizes, study 
design and the availability of neonatal data.  
Excess deaths in CAH have been attributed to salt-wasting adrenal crises, particularly in 
male infants, in whom the external signs of CAH (ambiguous genitalia) are less apparent 
than in female infants (3). This preponderance of females identified with CAH in many 
studies, as in ours, might, therefore, be due to higher numbers of male infants dying, 
especially in the absence of neonatal screening (19). In our study, however, there was an 
increased mortality in men and women in middle age, with the mean age at death of CAH 
patients being 54.8 years, 18 years earlier than in the matched reference group. Mean ages 
at death were similar in male and female patients with CAH, at 53.3 years versus 55.8 years, 
respectively, and there were no deaths amongst CAH patients under the age of 13 years. It 
should be noted, however, that neonatal deaths occurring before the infant could be 
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registered at a primary-care practice would not have been captured in our data source. The 
mean age of death in the control group, at 72.8 years, was younger than might be expected 
from the background population. However, the CAH and control cohorts were relatively 
young, with mean age at start of follow up 23.3 years and mean follow-up 5 years, therefore 
one would expect the deaths that could be captured to be those occurring at a younger age. 
Depression in patients with CAH was 30% higher than controls, increasing to nearly 40% in a 
sensitivity analysis of pharmaceutically treated depression. Overall and by age group, the 
lifetime prevalences of both depression and pharmaceutically treated depression were 
higher in women with CAH. It has been suggested that the experiences of women affected 
by virilisation and corrective surgery for ambiguous genitalia may have lasting adverse 
effects on their quality of life (20–22). Previous studies of mental health in women with CAH 
have reported varying outcomes, with one UK study reporting scores for psychological 
outcomes within normal ranges (23) and another, again in UK patients, reporting increased 
scores for depression in females with classic CAH but not in those with the non-classic form 
(2). A matched control study in 70 Danish women with disorders of sex development, of 
whom 33 had CAH, found that CAH was associated with impaired quality of life and greater 
affective distress (24). In our study, the prevalence of depression varied according to age 
and gender: the lifetime prevalence of depression was twice as high in children and nearly 
70% higher in men of 41 years and older. Arlt and colleagues (2) reported increased scores 
for depression in male patients with classic CAH, compared with matched controls, while 
Falhammar and colleagues (25) reported increased psychiatric disorders in male Swedish 
patients with CAH, with older patients born before the introduction of neonatal screening in 
1986 being most affected. One observation from our study that may be related to these 
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findings was that more patients with CAH than controls described themselves as ‘ex-
drinkers’. Further work on associations between alcohol and CAH would be interesting. It is 
also worth considering that the burden of CAH falls not only on the patient but also on their 
family: the parents of young children with CAH take on the role of primary caregiver, 
managing complex treatment regimens and the frequent, intercurrent childhood illnesses 
that could lead to adrenal crisis. Parents interviewed about their experiences have reported 
stress, anxiety, and disruption to their sleep and working lives (26). 
Annual mean healthcare costs were greater for CAH patients than their controls and greater 
for children than for adults. Mean costs in female CAH patients aged 0 to 6 years, at £8,147 
per year, were largely attributable to inpatient admissions and were nearly nine times 
higher than in age-matched controls. It is important to note that, because this study was 
based on primary-care data, the early neonatal period, the time when CAH characteristically 
presents, often as adrenal crisis, will not have been fully captured. Annual mean costs were 
lowest in the younger adult age group (aged 18 to 40 years); in female patients these 
remained significantly higher than in controls, but in male patients the position was 
reversed, with costs being significantly lower than in control patients. In older adults (aged 
41 years and over), annual mean costs were increased in absolute terms and were again 
higher than in control patients in all comparisons. In this age group, for the first time, mean 
costs in male patients with CAH were higher than in female patients. It is interesting to 
speculate whether this might be related to decreased healthcare utilisation for 
menstruation disorders or fertility as female patients approach menopause, or increased 
consultations in males, perhaps associated with cardiovascular risk (27), but this needs to be 
investigated further. Only one other study, to our knowledge, has examined healthcare 
Page 17 of 37
resource use and costs in patients with CAH, but the results were similar. This matched-
cohort study (28) investigated healthcare burden associated with adrenal insufficiency in a 
US claims database and found that healthcare costs in the CAH cohort (n=551) were 
significantly higher than in matched, non-exposed patients, with mean expenditure 
(including pharmacy costs) in the year following index diagnosis of $7,677 vs $4,203, 
respectively. 
 
We found children to be more compliant with their medication than adults. This was 
expected, as their parents would typically take responsibility for administering medication 
and children generally receive closer medical follow-up to monitor growth and 
development. However, even in the two paediatric age groups, just under 20% of patients 
were identified as non-compliant. Deficiencies in the transition of CAH patients from 
paediatric to adult care are well recognised (29) and are confirmed in this study, with a third 
of adult patients being non-compliant based on a medical possession ratio <80%. Non-
compliance with glucocorticoid replacement therapy in CAH patients, with associated 
androgen excess, has been linked to reduced final adult height, impaired fertility, and brain 
abnormalities in magnetic resonance imaging (30–32). In addition, analysis of a US claims 
database has demonstrated that healthcare expenditure is reduced in patients with adrenal 
insufficiency who are compliant with glucocorticoid replacement therapy (28).  
This study, in common with other analyses of real-world data sources, has a number of 
limitations. Even though the validity of medical diagnoses in CPRD (and its precursor, the 
General Practice Research Database) has been confirmed in several studies (33, 34), the use 
of a primary-care data set can be seen as a study limitation, given that the diagnosis and 
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initial care for CAH will have been delivered in a hospital setting. Our requirement that all 
CAH patients should have at least one record of corticosteroid prescription in order to 
substantiate status led to the exclusion of approximately 45% of patients, which is 
suggestive that at least a proportion of the excluded patients received their medication in 
secondary care, which would not be recorded in the database. Due to the complexities of 
CAH, the primary-care practitioner in the UK is unlikely to have been responsible for its 
diagnosis or its initial treatment, which will have been undertaken instead by secondary-
care specialists. However, ongoing treatment when the disease is under control and 
patients have reached adulthood will, for the majority of patients, be delivered in primary 
care. Consequently, there exists a selection bias in our study by which younger patients and 
those otherwise in an early or unstable stage of the disease may be under-represented, and 
the overall disease burden of CAH underestimated. The requirement of at least one 
corticosteroid prescription may also have introduced an immortal time bias, excluding 
patients with CAH who died before responsibility for their therapy could be taken on by the 
CPRD practice. Here again, this may have led to an underestimation of mortality. 
Adrenal crisis, especially in the absence of neonatal screening, is a relatively common 
presentation in males with classic CAH, typically occurring at two weeks or younger (35). 
However, costs relating to these periods of critical care will have been under-represented in 
our study because the patient will not usually be registered with a CPRD practice at that age 
and because specific costs for neonatal and paediatric critical care are not included in the 
UK National Tariff, which was our source for costing inpatient admissions. An indicative cost 
of £1,000 per bed day is, however, listed in the 2013/14 NHS Reference Costs for paediatric 
critical care not requiring ventilation (17).
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The prevalence for our studied patients in the data set was 1: 17,135, which is slightly higher 
than that implied by the incidence of 1:18,000 live births reported by the British Paediatric 
Surveillance Unit (4). Nevertheless, it is apparent that the healthcare burden of CAH in the 
UK remains to be fully elucidated. 
A potential weakness of our study lies in our use of non-exposed control patients instead of 
patients with other chronic inborn diseases in our analyses of healthcare use and costs. Over 
98% of the UK population is registered with a primary-care practice.(36) Therefore, a non-
exposed control population derived from a source such as CPRD, particularly one in which 
patients are matched by age to a relatively young cohort of exposed patients, will almost 
certainly be largely composed of healthy individuals. Indeed, the Charlson comorbidity index 
generated for our adult control population (based on 19 clinical conditions, including 
diabetes and malignant tumour) has an interquartile range of zero, suggesting low co-
morbidity. A marked difference in costs between the CAH and control population is not 
unexpected therefore. However, for healthcare organizations considering the cost-
effectiveness of new therapies or patient pathways, the incremental cost of care over the 
background population is an important measure. The value of our analyses lies in the 
detailed stratification of that incremental cost, which provides the economic context against 
with which to evaluate novel interventions for CAH. A comparison of healthcare costs in 
CAH with those in other inborn diseases falls outside the scope of this particular study but 
would merit future attention. 
 limitation in our analysis of depression also arises from the nature of the data source: in 
the necessity of setting the CAH patients’ index dates (and start of follow-up) as the later of 
their practice registration date and their first record of CAH. There is reason to believe that 
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the distribution of diagnoses, including that of depression, may cluster around the 
registration period, when patient histories are taken and initial health checks carried out. 
The design of our comparative analysis only required that the matching reference patient be 
registered at the CAH patient’s index date. Consequently, the peri-registration period was 
less well captured in the control arm of the study, which would have led to ascertainment 
bias if the outcome of depression were defined as incident depression subsequent to index 
date. We were therefore obliged to define the depression outcome as the lifetime 
prevalence of that condition. 
In our analysis of treatment adherence, days’ supply was identified from prescriptions 
recorded as having been issued by the primary-care practice. We have no record of whether 
those prescriptions were filled at a pharmacy or whether any of the supplied medicine was 
taken by the patient; our estimates of adherence are therefore conservative.  
In conclusion and taking into account the above limitations, this is to our knowledge the first 
analysis of the health burden of CAH using long-term routine healthcare records. The 
findings that rates of depression and all-cause mortality are higher in CAH patients tally with 
the findings of long-term registry studies, such as those carried out in Sweden (3), and, 
unsurprisingly, these are reflected in patients’ higher utilisation of healthcare resources. 
Before the introduction of glucocorticoid therapy in the 1950s, patients with CAH rarely 
survived into middle age. Although glucocorticoid therapy revolutionised the prognosis of 
the disease, much as insulin therapy transformed the care of type 1 diabetes, there has 
been a period of stasis in the treatment of this disease. The findings from this and other 
long-term studies demonstrate that further advances in therapy for patients with CAH are 
required to improve patients’ quality and duration of life.  
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Figure legends 
Figure 1 | Kaplan–Meier curves comparing all-cause mortality in eligible patients with 
congenital adrenal hyperplasia and matched control patients: a) female patients b) male 
patients, and c) all patients 
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 Table 1 | Baseline characteristics of matched CAH and control patients at index date* 
 
All patients Females Males 
CAH patients Control patients 
p-
value CAH patients Control patients 
p-
value CAH patients Control patients 
p-
value 
Patients aged <18 years  
 
 
 
   
 
Patients, n (%) 255 (—) 2,550 (—)  132 (52%) 1,320 (52%)  123 (48%) 1,230 (48%)  
Index year, median (IQR) 2003 (1996 to 2009) 2003 (1996 to 2009) 1.000 2004 (1996 to 2008) 2004 (1996 to 2008) 1.000 2001 (1996 to 2009) 2001 (1996 to 2009) 1.000 
Age at index, years 
  
 
   
 
    
 
Mean (SD) 5.1 (5.0) 5.1 (5.0) 1.000 5.8 (5.2) 5.8 (5.2) 1.000 4.5 (4.8) 4.5 (4.8) 1.000 
Median (IQR) 4 (0 to 9) 4 (0 to 9) — 5 (1 to 9) 5 (1 to 9) — 3 (0 to 7) 3 (0 to 7) — 
CAH duration, years** 
  
 
   
 
   
 
Mean (SD) 21.1 (3.9) (—) (—) — 2.5 (4.4) (—) (—) — 1.6 (3.2) (—) (—) — 
Median (IQR) 0 (0 to 2.2) (—) (—) — 0 (0 to 3.1) (—) (—) — 0 (0 to 1.0) (—) (—) — 
Patients aged ≥18 years 
   
Patients, n (%) 307 (—) 3,070 (—) — 199 (65%) 1,990 (65%) — 108 (35%) 1,080 (35%) — 
Index year, median (IQR) 2003 (1998 to 2008) 2003 (1998 to 2008) 1.000 2002 (1998 to 2008) 2002 (1998 to 2008) 1.000 2004 (1998 to 2009) 2004 (1998 to 2009) 1.000 
Age at index, years 
    
 
   
 
    
 
Mean (SD) 35.4 (15.2) 35.4 (15.2) — 34.3 (13.7) 34.3 (13.7) — 37.5 (17.4) 37.5 (17.3) — 
Median (IQR) 31.0 (25 to 41) 31.0 (25 to 41) 1.000 31.0 (24 to 39) 31.0 (24 to 39) 1.000 31.0 (25 to 47) 31.0 (25 to 47) 1.000 
CAH duration, years** 
   
 
   
 
   
 
Mean (SD) 14.2 (14.2) (—) (—) — 12.6 (13.5) (—) (—) — 17.2 (15.0) (—) (—) — 
Median (IQR) 11.8 (0 to 26.3) (—) (—) — 5.8 (0 to 24.2) (—) (—) — 19.5 (0 to 28.1) (—) (—) — 
BMI, kg/m
2
 28.2 (6.5) 26.1 (6.0)  28.4 (7.5) 26.1 (6.2) — 27.9 (4.9) 26.2 (5.6) — 
    Mean (SD) 28.2 (6.5) 26.1 (6.1) — 28.4 (7.5) 26.1 (6.2) — 27.9 (4.8) 26.2 (5.6) — 
    Median (IQR) 26.7 (23.3 to 31.2) 24.8 (22.1 to 29.0) <0.001 26.0 (22.7 to 33.1) 24.5 (21.7 to 29.3) 0.007 27.7 (24 to 30.9) 25.5 (22.7 to 28.7) 0.007 
    Missing values 157 (51%) 2,276 (74%) — 113 (57%) 1,448 (73%) — 44 (41%) 828 (77%) — 

 
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All patients Females Males 
CAH patients Control patients 
p-
value CAH patients Control patients 
p-
value CAH patients Control patients 
p-
value 
Systolic blood pressure, mmHg 
    
 
    
 
    
 
Missing values, n (%) 140 (46%) 1,898 (62%) — 95 (48%) 1,135 (57%) — 45 (42%) 763 (71%) — 
Mean (SD) 123.8 (16.4) 124.3 (16.8) 0.735 121.7 (16.3) 122.0 (16.3) 0.853 127.4 (15.9) 130.5 (16.4) 0.164 
Smoking status, n (%)            
Missing 13 (4%) 243 (8%) — 7 (4%) 113 (6%) — 6 (6%) 130 (12%) — 
Never smoked 174 (57%) 1,630 (53%) — 115 (58%) 1,125 (57%) — 59 (55%) 505 (47%) — 
Ex-smoker 32 (10%) 377 (12%) — 19 (10%) 224 (11%) — 13 (12%) 153 (14%) — 
Current smoker 88 (29%) 820 (27%) 0.495 58 (29%) 528 (27%) 0.643 30 (28%) 292 (27%) 0.580 
Alcohol status            
Missing 44 (14%) 611 (20%) — 33 (17%) 347 (17%) — 11 (10%) 264 (24%) — 
Never 59 (19%) 444 (14%) — 45 (23%) 322 (16%) — 14 (13%) 122 (11%) — 
Ex-drinker 12 (4%) 43 (1%) — 6 (3%) 27 (1%) — 6 (6%) 16 (1%) — 
Current drinker 192 (63%) 1972 (64%) 0.001 115 (58%) 1,294 (65%) 0.010 77 (71%) 678 (63%) 0.037 
Charlson index, median (IQR) 0 (0 to 1) 0 (0 to 0) <0.001 0 (0 to 1) 0 (0 to 0) 0.005 0 (0 to 1) 0 (0 to 0) 0.012 
* Start of data follow-up; defined as the latest of first CAH record (diagnosis or corticosteroid prescription), registration date, and practice up-to-standard date. 
** Time from first record of CAH (first diagnostic record or corticosteroid prescription) to index date. 
BMI, body mass index. CAH patients were matched to non-exposed control patients on year of birth, gender, general practice, linkage status, and registration at index date, with control patients inheriting the index date of their matched 
CAH patient. 
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Table 2 | Deaths, follow-up time, and crude event rates in eligible CAH patients and matched reference patients 
 

CAH patients  Control patients 
All patients  270 2,700 
Number of deaths  17  41  
Person-years  1,427  15,535  
Event rate (per 1,000 person-years)  11.9  2.6  
Males  117 1,170 
Number of deaths  7  21  
Person-years  575  6,592  
Event rate (per 1,000 person-years)  12.2  3.2  
Females  153 1,530 
Number of deaths  10  20  
Person-years  851  8,943  
Event rate (per 1,000 person-years)  11.8  2.2  
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Table 3 | Lifetime prevalence* of depression, identified by diagnostic code or antidepressant prescription, in CAH patients versus control 
patients 
 
Age at index date CAH patients Control patients 
Prevalence 
ratio 95% CI 
 
n Depression, n Prevalence, % n Depression, n Prevalence,% 
  
All ages 
        
     All patients 562 188 33.5% 5,620 1,467 26.1% 1.28 (1.13 to 1.45) 
     Female 331 133 40.2% 3,310 1,076 32.5% 1.24 (1.07 to 1.42) 
     Male 231 55 23.8% 2,310 391 16.9% 1.41 (1.10 to 1.80) 
Aged 17 years and younger 
        
     All patients 255 31 12.2% 2,550 211 8.3% 1.47 (1.03 to 2.09) 
     Female 132 19 14.4% 1,320 156 11.8% 1.22 (0.78 to 1.89) 
     Male 123 12 9.8% 1,230 55 4.5% 2.18 (1.20 to 3.96) 
Aged 18 to 40 years 
        
     All patients 226 97 42.9% 2,260 856 37.9% 1.13 (0.97 to 1.33) 
     Female 152 78 51.3% 1,520 662 43.6% 1.18 (1.00 to 1.39) 
     Male 74 19 25.7% 740 194 26.2% 0.98 (0.65 to 1.47) 
Aged 41 years and older 
        
     All patients 81 60 74.1% 810 400 49.4% 1.50 (1.30 to 1.74) 
     Female 47 36 76.6% 470 258 54.9% 1.40 (1.17 to 1.67) 
     Male 34 24 70.6% 340 142 41.8% 1.69 (1.32 to 2.17) 
* Records of depression were identified from patients’ ongoing data, post index date, and from past clinical histories where available 
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Table 4 | Total healthcare costs—combined NHS primary- and secondary-healthcare resource costs in eligible CAH and matched control 
patients  
 
  
CAH patients  Control patients  p-value  
  
Patients Resource cost per year, £  Patients  Resource cost per year, £    
   
Mean SD  Median IQR  
 
Mean  SD  Median IQR  
 
Aged 0 to 6 
years 
All  51 7,038  14,846  3,185  (1,860–5,187) 510 2,879  13,972  700 (465–1,482) <0.001 
Female  24 8,147  19,168  3,030  (1,558–4,410) 240 920 746 574 (415–1,250) <0.001 
Male  27 6,181  10,821  3,239  (2,060–5,249) 270 4,088  17,721  839 (496–1,595) <0.001 
Aged 7 to 17 
years 
All  33 3,766  7,494  2,183  (1,173–2,850) 330 1,232  2,451  491 (290–951) <0.001 
Female  18 4,582  9,671  2,021  (1,273–2,481) 180 1,447  3,175  544 (317–997) <0.001 
Male  15 2,588  2,112  2,407  (1,173–2,862) 150 1,050  1,660  397 (246–890) <0.001 
Aged 18 to 40 
years 
All  80 1,539  872 1,534  (1,099–1,787) 800 1,344  1,620  861 (511–1,600) 0.007 
Female  51 1,717  884 1,622  (1,373–2,005) 510 1,386  1,441  979 (558–1,734) <0.001 
Male  29 957 540 1,058  (425–1,137) 290 1,163  2,259  555 (284–874) <0.001 
Aged 41 and 
older 
All  42 4,204  4,863  2,029  (1,091–4,482) 420 1,651  2,303  934 (496–1,850) <0.001 
Female  25 3,619  4,375  1,595  (1,091–3,641) 250 1,491  2,373  837 (464–1,555) <0.001 
Male  17 5,014  5,547  2,536  (1,499–7,147) 170 1,921  2,172  1,002 (629–2,617) <0.001 
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Table 5 | Adherence to oral corticosteroid therapy by age group 
 
 
 n 
Age at first  
prescription*, 
years,  
mean (SD) 
Observation period,  
days, mean (SD) 
Supply, days, 
mean (SD) 
MPR, %,  
mean (SD) 
Non-compliant** 
patients, n (%) 
Aged 0 to 6 years 
           
All patients 181 1.9 (2.0) 1,076.5 (819.9) 975.1 (803.8) 88.9 (23.6) 29 (16.0%) 
Females 87 2.2 (2.1) 964.0 (817.5) 867.2 (797.9) 88.1 (24.9) 15 (17.2%) 
Males 94 1.6 (1.8) 1,180.6 (808.2) 1075.0 (796.2) 89.7 (22.2) 14 (14.9%) 
Aged 7 to 17  
           
All patients 203 9.3 (3.0) 1,934.7 (1,377.6) 1,729.6 (1,391.8) 87.3 (25.3) 37 (18.2%) 
Females 108 9.5 (3.2) 1887.6 (1,408.9) 1,669.7 (1,406.4) 86.0 (26.9) 22 (20.4%) 
Males 95 9.0 (2.8) 1988.3 (1,339.1) 1,797.7 (1,371.8) 88.7 (23.3) 15 (15.8%) 
Aged 18 or older 
           
All patients 396 31.3 (15.6) 2,425.9 (2,366.0) 1,847.4 (2,084.9) 78.4 (29.5) 141 (35.6%) 
Females 246 31.2 (14.5) 2515.7 (2,471.2) 1,920.1 (2,153.9) 78.5 (29.3) 87 (35.4%) 
Males 150 31.6 (17.3) 2278.6 (2,174.4) 1,728.1 (1,960.8) 78.3 (29.8) 54 (36.0%) 
* First prescription while patient within age group. 
** Non-compliance defined here as having a medical possession ratio (MPR) <80%. 
 

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